Many insect-protected crops express insecticidal crystal (Cry) proteins derived from the soil bacterium Bacillus thuringiensis (Bt), including both naturally-occurring Cry proteins and chimeric Cry proteins created through biotechnology. The Cry51Aa2 protein is a naturally-occurring Cry protein that was modified to increase its potency and expand its insect activity spectrum through amino acid sequence changes. The improved Cry51Aa2 variant, Cry51Aa2.834_16, and other developmental variants belong to the ETX_MTX2 family of proteins but share a low level of sequence similarity to other members of this family. This similarity is largely localized to the pore-forming and oligomerization protein domains, while sequence divergence is observed within the head domain that confers receptor binding specificity. The intact Cry51Aa2.834_16 protein was heat labile at temperatures !55 C, and was rapidly degraded after exposure to the gastrointestinal protease pepsin. No acute oral toxicity was observed in mice for three protein variants of Cry51Aa2, including Cry51Aa2.834_16, at doses exceeding 1000 mg/kg body weight. The weight-of-evidence therefore supports the conclusion of safety for Cry51Aa2.834_16 and demonstrates that amino acid sequence modifications can be used to substantially increase insecticidal activity of a protein without an increased hazard to mammals.
Introduction
Genetic modification (GM) of conventional crops enables safe and sustainable insect pest control in crop production systems. One of the more common approaches in insect-protected GM crops is expression of insecticidal proteins derived from the commonly occurring soil bacterium Bacillus thuringiensis (Bt) to provide intrinsic insect protection (Koch et al., 2015) . Insecticidal activity of Bt proteins has been known for almost 100 years (Ibrahim et al., 2010) and more than 700 genes coding for insecticidal Bt crystal (Cry) proteins have been identified (Palma et al., 2014) . Commercial Bt-derived products have been used worldwide for over 50 years and hundreds of Bt biopesticide formulation registrations are in place globally including in the United States, European Union, and China for the control of a wide variety of insect pests (Koch et al., 2015) . These products can be safely applied in both conventional and organic agricultural production (Sanchis and Bourguet, 2008) .
Proteins from Bt microbes, which include the Cry proteins as well as the cytolytic proteins (Cyt), vegetative insecticidal proteins (Vip), and others, provide control against insects from the lepidopteran, coleopteran, hemipteran, and dipteran orders, as well as against nematodes (Palma et al., 2014) . The selective toxicity of Cry proteins to insects is facilitated through specific receptor-mediated interactions. The extensive use of Bt-derived biopesticide products worldwide is due in part to their specificity against target insect pest species and lack of mammalian toxicity, assuring limited potential for impacts to beneficial insect species and non-target organisms, including other invertebrates, birds, aquatic organisms and mammals (Koch et al., 2015) . Due to their efficacy and extensive history of safe use and a favorable environmental degradation profile, Bt Cry proteins have been expressed in GM crops to confer insect-protection (Koch et al., 2015) .
Effective insect resistance management in agriculture and the ability to achieve the desired insect activity spectrum can be accomplished through the addition of other proteins outside of the classical three domain a pore-forming Cry protein structural class (Palma et al., 2014) . Pore-forming proteins (PFPs) are nearly ubiquitous in nature, produced by bacteria, fungi, and plants, as well as fish and amphibians (Moar et al., 2017) . Proteins in this class confer insect control by inserting into cell membranes within the insect intestinal tract leading to formation of pores that impact the integrity of the insect midgut and enable colonization by Bt spores, culminating in insect death (Bravo et al., 2007) . Specificity of insecticidal Bt proteins is mediated in part by their activation by proteases and their binding to specific receptors along the brush border membrane within the insect midgut (Bravo et al., 2007) . These specific Bt-toxin receptors are not present in humans or other mammals nor in non-target insects (as reviewed by (Koch et al., 2015) ), eliminating potential hazards related to exposure in humans, animals and the majority of non-target insects.
PFPs can be classified into two large groups a-PFPs and b-PFPs, based on the structures utilized to form a membrane-integrated pore (a-helices or b-barrels) and these mechanisms can be classified with a high rate of accuracy through the use of bioinformatics (Dal Peraro and van der Goot, 2016) . b-PFPs potentially provide a diverse source of new insecticidal proteins for commercial pest control in a wide variety of crops. Safety of b-PFPs in crops used for food and feed is demonstrated by the safe use of a binary toxin complex that includes Cry35Ab1, a Toxin_10 family b-PFP.
Cry35Ab1 works together with a non-b-PFP partner protein Cry34Ab1 to control coleopteran pest species such as corn rootworms, yet this binary protein complex is safe for humans and animals as evidenced by its narrow activity spectrum, digestibility, empirical mammalian safety data, and safe use on millions of acres in the U.S. annually since 2006 (Juberg et al., 2009; Moar et al., 2017) . b-PFP safety is also supported by the presence of these proteins in safely consumed foods including: spinach, cucumber, wheat, and fish such as cod and tilapia (Moar et al., 2017) .
A variety of insects can cause significant damage to cotton crops. Currently, commercial cotton varieties expressing Bt proteins provide excellent control of traditional cotton pests such as lepidopteran insects, but have limited efficacy for control of hemipteran insects that are emerging as economically important pests of cotton in the United States. The Bt protein Cry51Aa2 was shown to have insecticidal activity against two hemipteran pests in cotton; Lygus lineolaris and Lygus hesperus (Baum et al., 2012) . Cry51Aa2 is a member of the expansive ETX_MTX2 b-PFP protein family and accordingly shares a similar structure ( Fig. 1 ) and general functional similarity with a number of other insecticidal Cry proteins and ETX_MTX2 members. Millions of pounds of biopesticides that contain the b-PFPs Cry60Aa1 and Cry60Ba1 from Bt israeliensis and the b-PFPs BinB, MTX2, and MTX3 from Lysinobacillus sphaericus have been widely used to control mosquitoes in the U.S. and have been extensively used in potable water to control disease vector mosquitoes and blackflies in Africa (Moar et al., 2017) . This demonstrates their history of safe use and strongly supports the safety of this structural class of insecticidal proteins for use in GM crops.
Although Cry51Aa2 is a member of the ETX_MTX2 b-pore forming protein family (Moar et al., 2017) , this protein has significant sequence divergence from other ETX_MTX2 family members, enabling its specificity and limiting its activity spectrum (Bachman et al., 2017) , thereby limiting its potential to impact non-target organisms.
Enhancing control of Lygus pests to a commercial level of efficacy was achieved through selected amino acid modifications (i.e. selective substitutions and deletions) to the Cry51Aa2 protein, which substantially increased the insecticidal activity of the resulting variant Cry51Aa2.834_16 relative to the wild-type Cry51Aa2 protein (Gowda et al., 2016) . As described by Gowda and colleagues, these modifications to Cry51Aa2 consisted of eight amino acid substitutions (F46S, Y54H, S95A, F147S, Q149E, S167R, P219R, R273W) and the deletion of a single HYS motif from the HYS repeat in residues 196e201. These iterative amino acid substitutions and deletions were made through targeted DNA sequence changes to the Cry51Aa2 coding sequence followed by bioassay screening of each protein variant. These sequence changes also ensured effective control of targeted hemipteran (Lygus hesperus, Lygus lineolaris and Pseudoalomoscelis seriatus) and thysanopteran (Frankiniella spp.) insect pests. When mapped to the three-dimensional crystal structure of the protein, these modifications were primarily but not exclusively localized to the receptor binding region, or "head region", of the protein (Gowda et al., 2016) . This information taken together with Cry51Aa2.834_16 binding studies conducted by Jerga and colleagues (Jerga et al., 2016) supports the assertion that sequence and structural diversity in the head region of b-PFPs contributes to differential receptor binding that, in turn, confers target species specificity (Moar et al., 2017) .
The food and feed safety of proteins introduced into GM-derived crops can be assessed using a tiered, weight-of-evidence based approach (Delaney et al., 2008; Hammond et al., 2013; OECD, 2002) . Evidence from the first tier of this framework can be built by taking some of the following elements into consideration: (a) history of safe use/consumption in food, (b) the source organism from which the protein is derived and its mode of action, (c) a bioinformatics analysis providing a structural comparison (e.g., primary amino acid sequence homology) to proteins with a known history of safe use, (d) a bioinformatics analysis providing a structural comparison (e.g., primary amino acid sequence homology) to known allergens, toxins or other biologically active proteins known to have adverse effects in mammals, (e) characterization of the physicochemical and functional properties of the protein, and (f) stability of the protein to degradation by digestive proteases such as pepsin and pancreatin and to heat treatment (as would occur during processing and/or cooking). The second tier of the framework evaluates the potential for mammalian toxicity in vivo. Utilizing this framework, a weight-of-evidence approach is utilized to demonstrate safety of the protein(s) for human and animal consumption.
The weight-of-evidence from Tier I and Tier II safety assessments presented herein supports the safety of three Cry51Aa2 variants: Cry51Aa2.834, Cry51Aa2.834_2 and Cry51Aa2.834_16. These data make a strong case for the relative safety of proteins with amino acid sequence changes that significantly improve activity, when structure and function are conserved. Fig. 1 . Structural similarity among Cry51Aa2 variants and structural divergence from epsilon toxin. Head (receptor binding) and tail (pore forming and oligomerization) regions of Clostridium perfringens epsilon toxin in gray and salmon color (ETX; Cole et al., 2004 ) (A) and the three amino acid sequence variants Cry51Aa2.834, Cry51Aa2.834_2 and Cry51Aa2.834_16 in purple and teal (B) and the two figures overlaid (C). The structures for ETX and Cry51Aa2.834_16 were experimentally determined while those for Cry51Aa2.834 and Cry51Aa2.834_2 were created through homology modeling.
Materials and methods

Production and purification Cry51Aa2 proteins
Molecular cloning and expression in Bacillus thuringiensis (Bt) of three variants of the Cry51Aa2 protein, Cry51Aa2.834 Cry51Aa2.834_2, and Cry51Aa2.834_16 was conducted as described previously (Baum et al., 2012; Gowda et al., 2016) . Isolation and purification of these proteins was conducted from Bt cell fermentation products. Briefly, proteins were extracted from Bt cell fermentation paste using 50 mM sodium carbonate/bicarbonate buffers (pH~10.5e10.8). The supernatants were clarified by centrifugation and the proteins were purified from the resulting supernatant. For the Cry51Aa2.834_16 protein, 1 M NaCl was utilized to precipitate contaminating proteins prior to centrifugation. Purification was conducted using a combination of anion exchange chromatography and ultrafiltration.
Characterization of the Cry51Aa2 protein variants
All methods used to characterize the Cry51Aa2 amino acid sequence variant proteins have previously been reported (Wang et al., 2015 (Wang et al., , 2016 and were similarly employed to characterize the three Cry51Aa2 variants employed in the experiments described herein. The concentration of total protein was determined using quantitative amino acid compositional analysis. Purity and apparent molecular weight of the proteins were determined using densitometric analysis of Coomassie stained SDS-PAGE gels. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) was used to confirm protein identity (Aebersold, 1993; Billeci and Stults, 1993; Hileman et al., 2006) . For MALDI-TOF analysis, aliquots of the protein samples were digested by trypsin, mixed with alpha-cyano-4-hydroxycinnamic acid and analyzed using an AB Sciex™ 5800 Mass Spectrometry System (Foster City, CA) in reflector mode. Signal-to-Noise was set to !10. Only monoisotopic ions were assigned in a mass list. A plate/default calibration was performed using TOF/TOF calibration standards. The mass spectra were searched against a protein sequence using Mascot and Protein Pilot protein identification tools. Peptide mass tolerance was ±0.5 Da and a fixed modification was carboxymethyl. N-terminal sequence analysis was performed by automated Edman-degradation chemistry using an Applied Biosystems 494 Procise Sequencing System (Hunkapiller and Hood, 1983; Wang et al., 2015) .
2.3. Bioinformatic assessment of potential Cry51Aa2.834_16 protein allergenicity and toxicity Bioinformatic assessments and thresholds used to assess any potential for allergenicity and/or toxicity were derived from those described previously by Wang et al. (2015) and outlined by Codex Alimentarius (2009) , the exceptions being that 2017 database versions were used and the full 35% identity over 80 amino acid threshold search was able to be conducted as the query sequences were of sufficient length to apply this criterion. The all protein database utilized included all protein sequences within GenBank release 217. The updated toxin database (TOX_2017) was compiled in the same manner described in Wang et al. (2015) whereby sequence descriptions were screened for the keywords "toxi" or ricin and this database contains 22,760 sequences. The allergen database (AD_2017) utilized was the "COMprehensive Protein Allergen REsource" (COMPARE) database as generated and maintained by the Health and Environmental Sciences Institute (HESI) (www.comparedatabase.org), and contains 1970 sequences. Alignments were generated using FASTA v36.3.5d with an E-score threshold of 1eÀ5 (1 Â 10 À5 ) being set as an initial threshold for alignment significance. This is the same threshold as used previously (Wang et al., 2015 (Wang et al., , 2016 and is recognized as being a conservative threshold for the identification of proteins that may be homologous (Pearson, 2003) .
Assessment of Cry51Aa2.834_16 protein susceptibility to pepsin
The susceptibility of the Cry51Aa2.834_16 protein to degradation by pepsin was assessed following a standardized protocol (Thomas et al., 2004) . Briefly, purified Cry51Aa2.834_16 (in 50 mM sodium carbonate/bicarbonate buffer, pH 10.8) was mixed with high purity pepsin (Sigma, St. Louis, MO) in 2 mg/ml NaCl, 10 mM HCl, pH~1.2 to a final protein-to-pepsin ratio of 1 mg total protein:10 U of pepsin. The reaction mixture tube was immediately placed in a 37 ± 2 C water bath. Samples were removed at 0.5, 2, 5, 10, 20, 30 and 60 min and were immediately quenched by the addition of sodium carbonate and 5X SDS-PAGE sample loading buffer (~310 mm Tris-HCl, 25% (v/v) 2-mercaptoethanol, 10% (w/v) sodium dodecyl sulfate, 0.025% (w/v) bromophenol blue, 50% (v/v) glycerol, pH 6.8). Protein only and pepsin only experimental controls were also prepared and incubated for 60 min in a 37 ± 2 C water bath. All resulting samples were heated at 95e100 C for 5e10 min, frozen on dry ice, and stored in a À80 C freezer prior to SDS-PAGE analysis.
Heat lability of Cry51Aa2.834_16 protein
Aliquots of the purified Cry51Aa2.834_16 protein at a final total protein concentration of 1.0 mg/ml in 50 mM sodium carbonate/ bicarbonate were placed at the following temperatures and incubated for 15 min: 25, 37, 55, 75, or 95 C ± 2 C. Following heat treatment, samples were immediately placed on wet ice. A control sample aliquot of the Cry51Aa2.834_16 protein was also maintained on wet ice throughout the course of the heat treatment incubation period. Following heat treatment, insecticidal activity of the Cry51Aa2.834_16 protein in each sample was analyzed as described below.
Insect diet bioassays
Cry51Aa2.834_16 protein activity was evaluated using a Western tarnished plant bug (WTP, Lygus hesperus) diet-incorporation insect bioassay to evaluate the heat stability and to confirm insecticidal efficacy of the test dosing solutions for the acute mouse gavage study. The assay conditions and model system are as described by Gowda and colleagues (Gowda et al., 2016) . Cry51Aa2.834_16 dosing solutions in water were diluted into a liquid Lygus diet (Frontier Agricultural Services). Each bioassay replicate consisted of a series of six dilutions from 0.38 to 12 mg Cry51Aa2.834_16/ml diet with a two-fold separation factor between dilutions to enable estimation of the LC 50 value (lethal concentration eliciting 50% mortality). Diet mixtures were dispensed (150 mL/well) into a 48-well diet sachet created by a vacuum manifold and heat sealed with mylar. The sachet was cut into individual diet domes; thirty-two domes were selected per treatment based on completeness of seal and placed into individual wells of a 128-well tray. Each well was targeted for infestation with a single acclimated WTP nymph ( 30 h after first observation of hatching). Both the number of insects infested and the number surviving were recorded for each treatment level following a sixday incubation period at 27 C.
Acute oral toxicity assessment of three Cry51Aa2 variants
Acute oral toxicity studies were conducted in CD-1 mice. An oral route of exposure was selected because it is the most likely route of human exposure and an acute toxicity study was chosen because most known protein toxins demonstrate an acute onset of adverse effects (Hammond and Fuchs, 1998) . Two studies were conducted and the study protocols were based on the US EPA OPPTS Guideline 870.1100 (EPA, 1998). The first study was conducted for protein safety characterization of two early developmental protein variants and was not performed according to Good Laboratory Practices (GLPs), whereas, the second study was run for regulatory purposes with the commercial candidate protein and was conducted according to GLPs. In the first study, the test substances were Cry51Aa2.834 and Cry51Aa2.834_2 and in the second study, the test substance was Cry51Aa2.834_16. The Cry51Aa2.834 and Cry51Aa2.834_2 dosing solutions were prepared with a vehicle buffer (1 mM sodium carbonate, pH 10.0) at a dose concentration of 16.1 and 18.5 mg/ml, respectively, to enable a target dose level of 1332 mg/kg body weight. The Cry51Aa2.834_16 dosing solution was prepared in 10 mM sodium carbonate/bicarbonate vehicle buffer but at a dose concentration of 77.4 mg/ml to enable a target dose level of 5000 mg/kg body weight. In addition to the test dosing solutions, vehicle dosing solutions were prepared for each study. In the study with Cry51Aa2.834_16, a protein control dosing solution in vehicle was also included that contained bovine serum albumin at a concentration of 77.4 mg/ml to enable a target dose level of 5000 mg/kg. Different dose levels and experimental approaches were used in the acute toxicity studies, as Cry51Aa2.834 and Cry51Aa2.834_2 were early improved variants tested for early product development screening rather than regulatory purposes. For these proteins, there was limited protein availability at the time of testing. In contrast, Cry51Aa2.834_16 was the commercial candidate for which more protein was available for testing and for which higher dose levels were needed for regulatory purposes. It is important to note, however, that all tested dose levels are considered appropriate for hazard characterization in part because substances routinely consumed safely in food have exhibited toxicity at far lower doses (e.g. caffeine).
Prior to the start of the toxicity studies, the identities of Cry51Aa2.834 and Cry51Aa2.834_2 were confirmed by mass fingerprint analysis and the identity of the Cry51Aa2.834_16 protein was confirmed by mass fingerprint analysis, N-terminal sequencing, and by immunoblot. Insecticidal efficacy was confirmed by insect bioassay as described above. The concentration, purity, and stability of all test proteins were confirmed by amino acid analysis (concentration) and by SDS-PAGE analysis (purity and stability) prior to study start. The pH and protein concentration of the test, control, and vehicle dosing solutions were assessed prior to study start in the study with Cry51Aa2.834_16. Additional samples of the dosing solutions in this study (as appropriate) were collected prior to the first dose to assess concentration (BioRad method), purity, molecular weight and stability (SDS-PAGE), homogeneity and insecticidal efficacy (via insect bioassay) and after the second dose to assess concentration, purity, stability, and efficacy.
Male and female CD-1 mice were obtained from Charles River Laboratories. At the time of randomization, the animals selected for study were approximately 7e8 weeks of age with body weights ranging from 30 to 35 g for the males and 24e28 g for the females. On the day of dosing (Day 0), the animals chosen for use on study were weighed and fasted approximately 3e4 h prior to dose administration and between doses. The dosing solutions were administered in 2 doses, each with a dose volume of 33.3 ml/kg body weight (approximately 4 h apart) by oral gavage to groups of 3 males and 3 females for the Cry51Aa2.834 and Cry51Aa2.834_2 proteins and 10 males and 10 females for the Cry51Aa2.834_16 protein. The dosing volume for each animal was based on the nonfasted body weights on Day 0. Animals were observed for general health/mortality and morbidity twice daily, throughout the studies for 14 days. Additionally, each animal was removed from the cage for detailed clinical observations, two times on Day 0 (once before dosing and once after dosing) and then once daily thereafter (Days 1e14). Individual body weights were recorded on Day 0 prior to fasting, Day 0 prior to dosing, and on Days 7 and 14. In the study with Cry51Aa2.834_16 protein, food consumption was also measured for the intervals from Days 0e7 and 7 to 14. All animals were euthanized on Day 14 by carbon dioxide inhalation and were subjected to a complete gross necropsy examination. Animal welfare was a key priority for these studies and all animal work was conducted in an AAALAC accredited facility and protocols were reviewed and approved by the test facility IACUC committee prior to study conduct.
Statistical analysis of acute toxicology data
Toxicology data were statistically analyzed for body weight, body weight gain and food consumption. In the acute study conducted with Cry51Aa2.834 and Cry51Aa2.834_2 data sets for each interval were initially analyzed for homogeneity of variance using Levene's test (Levene, 1960) followed by the Shapiro-Wilk test for normality (Shapiro and Wilk, 1965) . A single-factor parametric analysis of variance (ANOVA) was applied if neither Levene's test or the Shapiro-Wilk test were significant (p < 0.0001). Dunnett's test was used (p < 0.05) to identify statistically-significant differences between the control and each test substance-treated group (Dunnett, 1955 (Dunnett, , 1964 Snedecor and Cochran, 1998) . A KruskalWallis non-parametric ANOVA (Kruskal and Wallis, 1952) was applied if either Levene's test and/or the Shapiro-Wilk test were significant. Dunn's test (Dunn, 1964) was used (p < 0.05) if the nonparametric Kruskal-Wallis ANOVA was significant (p < 0.05) to identify statistically-significant differences between the control and each test substance-treated group.
In the toxicology study conducted with Cry51Aa2.834_16, Levene's test was used to assess homogeneity of group variances (p < 0.05). Datasets with at least 3 groups were compared using an overall one-way ANOVA F-test or Kruskal-Wallis test (if Levene's test was significant). If the overall test was significant (p < 0.05), pairwise comparisons were conducted using a two-sided t-test or the Wilcoxon Rank-Sum test, respectively. Pairwise comparisons that were significant were reported at the <0.001, <0.01, and <0.05 significance levels (adjustments for the p-values for the t-test and Wilcoxon Rank-Sum test were performed by multiplying them by the square root of the number of pairwise comparisons). Differential statistical analysis approaches between the two studies reflect changes in laboratory information management/data collection systems at the contract laboratory conducting these studies and the inherent statistical constraints within these systems. Despite slight differences in statistical approaches, the methodologies are similar and are suitable for the statistical evaluation of any potential adverse effects of the tested proteins in mice.
Results
Purification and characterization of the Cry51Aa2 protein variants
The Cry51Aa2 protein variants were expressed in and purified from a toxin free Bt host strain (Baum et al., 2012) . Following optimization of purification conditions, these proteins were isolated from Bt cell fermentation products and enriched to >99% purity (Table 1, Supplemental Fig. 1 ). All characterization data are presented in Table 1 . The three variants of the Cry51Aa2 protein presented the expected apparent molecular weight of~34 kDa, as assessed by SDS-PAGE analysis. The identities of the Cry51Aa2.834, Cry51Aa2.834_2 and Cry51Aa2.834_16 proteins were confirmed by tryptic peptide mass mapping using MALDIeTOF/TOF MS analysis, which resulted in 45%, 36% and 55% coverage of the entire protein sequence, respectively. These sequence coverages are sufficient to confirm their identity as protein identification is considered reliable if the coverage is at least 15% of the sequence (Jensen et al., 1997; Raybould et al., 2013) .
Bioinformatics analyses of Cry51Aa2 variants for similarity to known protein allergens and toxins
Bioinformatics analyses to assess and evaluate whether or not the introduced protein shows any similarity to known toxins or allergens is seen as one of the key elements in the safety evaluation of proteins introduced into GM crops (Hammond et al., 2013; Kier and Petrick, 2008) . The bioinformatics analyses performed on all three Cry51Aa2 variants demonstrated highly congruent results (Tables 2 and 3) . Notably, no alignments to the COMPARE allergen database were observed for any of the three Cry51Aa2 variants (Data Not Shown), indicating no similarity to known allergens. Searches against the toxin database (TOX_2017) resulted in the same observation for each of the query sequences (Table 2) , with each alignment displaying an E-score of 1e-5 (1 Â 10 À5 ), the cutoff which has been used as a conservative threshold for alignment significance (Pearson, 2003; Wang et al., 2015 Wang et al., , 2016 . For each query, the best alignment to each of the Cry51Aa2 variants displayed low (<30%) levels of identity to the same protein annotated as "aerolysin toxin family protein" (GenBank Release 217, entry GI-1102943401; http://www.ncbi.nlm.nih.gov). This alignment was anticipated because aerolysin is a member of the ETX_MTX2 family of proteins (Cole et al., 2004 ) that also includes Cry51Aa2 protein and its variants (Moar et al., 2017) . Searches of all proteins in GenBank release 217 (http://www. ncbi.nlm.nih.gov) resulted in both identical and highly similar results. In the case of each query sequence, the alignment returned was to a 306 amino acid length sequences from a US patent (Table 3 ) which in each case (GenBank entries GI-1115466231, GI-1115466232, and GI-1115466244) simply represent their selfidentification. Subsequent alignments, with lower degrees of identity and homology, for each of the queries are to numerous publicly disclosed Bt-derived coleopteran and hemipteran insect active proteins. As discussed below, none of the searches against the all protein, toxin, or allergen databases results in any indication that the three evaluated Cry51Aa2 variant proteins (members of the b-PFP/ETX_MTX2 family of proteins) have the potential to result in human allergenicity or to elicit toxicity in humans or animals.
Assessment of Cry51Aa2.834_16 protein susceptibility to pepsin
Degradation of the Cry51Aa2.834_16 protein by pepsin was assessed using an established and standardized assay (Thomas et al., 2004) . Tier 1 bioinformatics screening did not indicate putative hazards for any of the Cry51Aa2 variants evaluated in this body of work and therefore, this pepsin assessment was made only for regulatory purposes in support of the commercial-track Cry51Aa2 variant Cry51Aa2.834_16. The resulting SDS-PAGE gel Fig. 1 ).
b Concentrations provided as mg protein per ml of diet. Values obtained from Gowda and colleagues (Gowda et al., 2016) . indicated that the intact Cry51Aa2.834_16 protein (~34 kDa) was completely degraded after incubation with pepsin at 37 C for 0.5 min (Fig. 2, Lane 5) , the earliest time point tested. A smaller peptide fragment of~4 kDa was observed at the 0.5 min time point but was completely degraded after 10 min of incubation with pepsin ( Fig. 2, Lanes 5e8 ). There was no change in the protein banding pattern for the protein when incubated at 37 C in the absence of pepsin, indicating that the observed protein degradation was a direct result of the proteolytic activity of pepsin and not due to instability of the protein when incubated at 37 C (Fig. 2 , Lanes 3 and 12). Additionally, there was no change in the protein band corresponding to pepsin (~38 kDa) when incubated at 37 C in the absence of Cry51Aa2.834_16, indicating that pepsin was stable at 37 C over the course of the experiment (Fig. 2 , Lanes 2 and 13).
Heat lability of Cry51Aa2.834_16 protein
The thermal stability of the Cry51Aa2.834_16 protein was evaluated by determining the LC 50 of the Cry51Aa2.834_16 protein in Lygus hesperus after incubating the protein at 25, 37, 55, 75, or 95 C ± 2 for 15 min (Table 4 ). The tier 1 bioinformatics screening did not indicate putative hazards for any of the Cry51Aa2 variants evaluated in this body of work and therefore, this thermal stability assessment was made only for regulatory purposes in support of the commercial-track Cry51Aa2 variant Cry51Aa2.834_16. When the Cry51Aa2.834_16 protein was incubated at 25 C and 37 C, it retained activity with LC50 values of 1.164 and 2.557 mg Cry51Aa2.834_16/mL diet, respectively. However, when heated to temperatures of 55, 75 and 95 C for 15 min, the LC 50 values were >60.0 mg Cry51Aa2.834_16/mL diet, a reduction in activity of >95% relative to the control Cry51Aa2.834_16 protein.
Assessment of potential oral toxicity of the three Cry51Aa2 variants
For Cry51Aa2.834_16 and the other Cry51Aa2 variants, the Tier 1 assessment (e.g. bioinformatics and additional endpoints for Cry51Aa2.834_16) indicates that dietary exposure to these proteins will not pose a hazard to humans or animals. Nevertheless, acute oral toxicity studies in mice were conducted on the three Cry51Aa2 variants for further assurances of mammalian safety of these members of the b-PFP/ETX_MTX2 family of proteins.
Mice in the test groups were dosed with either Cry51Aa2.834, Cry51Aa2.834_2, or Cry51Aa2.834_16 at doses of 1332, 1332 and 5000 mg/kg, respectively. The three test proteins were active against L. hesperus and Cry51Aa2.834_16 was also active against L. lineolaris (Gowda et al., 2016) . Although not required in acute toxicity testing guidelines, homogeneity, stability, concentration, and insecticidal activity of dosing solutions were analytically confirmed for the GLP toxicology study with Cry51Aa2.834_16 and all analyses met the acceptability criteria for the respective analyses (data not shown). The test, control and vehicle dosing solutions were administered by oral gavage on study day 0 (as two doses 4 h apart) to the appropriate group of mice and the animals were observed for 14 additional days. No mortality occurred during these studies. There were no test-related differences in body weight or body weight gain observed in either of these studies and no statistically significant differences in these parameters were observed (Tables 5 and 6 ). There were no test substance-related differences in body weight or body weight gain observed in either of these studies and no statistically significant differences in these parameters were observed (Tables 5 and 6 ). There were no test substancerelated differences in food consumption in the study with Cry51Aa2.834_16 (Table 7) . Although food consumption was higher (p < 0.05) in the Cry51Aa2.834_16 test group males relative to the vehicle control group during the interval from study days 0 to 7, there was no significant difference relative to the BSA protein control, this difference was observed in males only during a single time interval, and was thus not considered to be treatment related or adverse. No test substance-related clinical or gross necropsy findings were observed. Therefore, neither Cry51Aa2.834, Cry51Aa2.834_2, or Cry51Aa2.834_16 exhibited any toxicity at 1332, 1332 and 5000 mg/kg respectively, the highest dose levels tested (Fig. 3) . an approximate ratio 1 mg total protein:10 U of pepsin (Lane 4) and incubation at 37 C (Lanes 5e11), the full length Cry51Aa2.834_16 protein is completely degraded. The Cry51Aa2.834_16 protein or pepsin incubated independently at 37 C for the duration of the experiment (Lanes 12 and 13, respectively) exhibited no change in band intensity. Approximate molecular weights (kDa) are shown on the left of the gel, and correspond to the molecular weight markers loaded. 
Discussion
Insect pests can present significant challenges to crop production (USDA, 2013) and continued innovation of biotechnology solutions is needed to ensure multiple crop-protection options for insect control are available to growers. Some of these biotechnology solutions may include GM crops expressing beta pore forming proteins (b-PFPs) that contain structural motifs that are ubiquitous in nature and therefore have a history of safe use (Moar et al., 2017) but are relatively new to agricultural biotechnology. These proteins share functional similarity with existing threedomain Cry proteins from Bt in that they bind to specific 31.6 ± 1.3 32.1 ± 1.4 NA 32.3 ± 2.1 32.6 ± 1.6 NA 32.7 ± 1.7 34.5 ± 1.1 NA Female 26.8 ± 0.9 26.5 ± 0.8 NA 27.8 ± 0.5 28.3 ± 0.9 NA 28.5 ± 0.8 29.6 ± 2.2 NA Cry51Aa2.834_2 1332 Male 31.8 ± 0.6 32.1 ± 1.4 NA 32.4 ± 1.4 32.6 ± 1.6 NA 34.2 ± 0.9 34.5 ± 1.1 NA Female 26.6 ± 1.3 26.5 ± 0.8 NA 27.0 ± 0.7 28.3 ± 0.9 NA 28.3 ± 0.9 29.6 ± 2.2 NA Cry51Aa2.834_16 5000 Male 32.5 ± 1.0 32.6 ± 0.9 32.2 ± 0.8 34.4 ± 1.3 34.5 ± 1.7 33.7 ± 1.2 35.4 ± 1.2 34.9 ± 2.3 34.9 ± 1.5 Female 24.1 ± 1.1 24.0 ± 1.3 24.4 ± 1.5 26.3 ± 0.9 26.2 ± 1.5 26.5 ± 1.6 28.0 ± 1.4 28.2 ± 1.5 27.9 ± 2.1
No statistically significant differences were observed by ANOVA with Dunnet's Test at p < 0.05. N ¼ 3 for study with Cry51Aa2.834 and Cry51Aa2.834_2; N ¼ 10 for study with Cry51Aa2.834_16. BW ¼ body weight; BSA ¼ Bovine Serum Albumin protein control. NA ¼ not applicable as treatment group was not present in study or endpoint was not measured in study. a There was only a vehicle control and no BSA control dosing solution in the study with Cry51Aa2.834 and Cry51Aa2.834_2. 
1332 Male 2.5 ± 1.8 2.0 ± 0.3 NA 1.8 ± 2.3 1.8 ± 0.5 NA Female 2.2 ± 0.9 3.1 ± 0.4 NA 1.3 ± 1.3 1.3 ± 1.5 NA Cry51Aa2.834_16 5000 Male 1.9 ± 0.4 1.8 ± 1.8 1.5 ± 0.6 1.0 ± 0.6 0.4 ± 1.4 1.2 ± 0.7 Female 2.2 ± 0.7 2.2 ± 1.2 2.1 ± 1.2 1.7 ± 0.9 2.0 ± 1.0 1.4 ± 1.5
No statistically significant differences were observed by ANOVA with Dunnet's Test at p < 0.05. N ¼ 3 for study with Cry51Aa2.834 and Cry51Aa2.834_2; N ¼ 10 for study with Cry51Aa2.834_16. BW ¼ body weight; BSA ¼ Bovine Serum Albumin protein control. NA ¼ not applicable as treatment group was not present in study or endpoint was not measured in study. a There was only a vehicle control and no BSA control dosing solution in the study with Cry51Aa2.834 and Cry51Aa2.834_2. Fig. 3 . No toxicity was observed in acute oral gavage toxicology studies with Cry51Aa2.834, Cry51Aa2.834_2 and Cry51Aa2.834_16. Dose levels reported here were the highest dose levels tested and did not produce toxicity in CD-1 mice in acute toxicity studies conducted with Cry51Aa2.834, Cry51Aa2.834_2, and Cry51Aa2.834_16. Mice were treated by oral gavage on study day 0 (as two doses 4 h apart) and were observed for body weights, food consumption, clinical signs, and gross pathology during/following a 14 day observation period.
receptors in the insect gut and form pores that enable insect control. As proteins with a familiar function and biological activity, the safety of b-PFPs can be evaluated within the existing weight-ofevidence protein safety assessment framework as described by Delaney and colleagues (Delaney et al., 2008 ) (See Section 1). The data presented in this report represents a comprehensive safety assessment of Cry51Aa2.834_16 using a multistep tiered weight-of-evidence approach. Cry51Aa2.834_16 is expressed in a new insect-protected cotton product, MON 88702, for the control of piercing-sucking insect pests (Gowda et al., 2016) . The efficacy of this protein was improved through the substitution of eight amino acids and a targeted deletion of three amino acids, resulting in 96% amino acid sequence identity of Cry51Aa2.834_16 to the wild-type Cry51Aa2 protein (Baum et al., 2012; Gowda et al., 2016) . As presented in this report, the improvements made to the efficacy of this protein were achieved without any impact to protein safety.
Bioinformatic analyses were conducted to determine if Cry51Aa2.834_16 (and two other early developmental variants of this protein, Cry51Aa2.834 and Cry51Aa2.834_2) had any sequence or structural similarity proteins having allergenic potential or the potential to elicit a toxic response. These analyses demonstrated that Cry51Aa2.834_16 and the other Cry51Aa2 variants are members of the b-pore forming family of proteins which includes ETX_MTX2 and aerolysin variants. This is further illustrated by comparing the structures of the Cry51Aa2 variants to other proteins in this family (Fig. 1) . There is limited sequence identity between these three proteins and the conserved tail region (pore forming and oligomerization domains) of known mammalian toxins (e.g. epsilon toxin and aerolysin), however, the tail region defines the protein family but not each protein's specificity. Cry51Aa2.834_16 and its companion developmental variants have significant sequence and structural diversity from other ETX_MTX2 family members in the receptor binding head domain that confers species specificity and consequently defines insecticidal activity spectrum (Jerga et al., 2016) . The relevance of these data to specificity is empirically demonstrated by the limited activity spectrum of this protein (Bachman et al., 2017) and by the mammalian safety data presented herein for three Cry51Aa2 variants. Therefore, the lowlevel alignment of Cry51Aa2.834_16 to pore forming and oligomerization regions of GenBank entry GI-1102943401 is consistent with the known domain architecture of Cry51Aa2 protein variants and other b-PFP family proteins, and when analyzed from a domain-based perspective, sequence diversity in the head domain illustrates the rationale for safety of these Cry51Aa2 variants. Taken together, this analysis demonstrates that integrating known domain-based architecture with amino acid sequence alignments provides additional information to enable the evaluation of protein safety. Jerga et al. (2016) demonstrated how the Cry51Aa2 protein variant Cry51Aa2.834_16 exerts its insecticidal effects in Lygus species and characterized the mode of action and specificity of Cry51Aa2.834_16 by elucidating how this protein binds to a specific receptor in brush border membranes of the gastrointestinal tract in L. lineolaris and L. hesperus. The importance of the receptor binding domains in contributing to specificity of b-PFPs has also been illustrated by a series of in vitro studies with another b-PFP, Cry41Aa (Parasporin 3), in which aromatic amino acid substitutions in the receptor binding region eliminated cytotoxicity to the cancer cell line HepG2 (Krishnan et al., 2017) . In contrast, unpublished dissertation research (from the same lead investigator) indicates that Cry51 is not toxic to the HepG2 cell line (http://sro.sussex.ac. uk/47169/) despite some structural similarity to Cry41Aa. The results of these in vitro studies confirm the importance of the receptor binding head domain for specificity of b-PFPs, lending further support to the concept of leveraging domain-based and structural analyses to complement primary sequence analysis as part of a comprehensive safety assessment.
Although the history of safe use, bioinformatic analyses, mode of action and specificity data strongly support the safety of Cry51Aa2.834_16, additional tests were conducted to determine the fate of the protein in the presence of heat or digestive enzymes. Protein structure can be lost in food processing due to changes in temperature, pH and other physical disruptions (Hammond and Jez, 2011) . As protein structure is a key determinant of potential toxicity, understanding the fate of a protein after exposure to heat and digestive enzymes provides additional information about the potential for exposure or toxicity following processing, cooking, and consumption of food and feed (Delaney et al., 2008; Hammond et al., 2013) .
Information regarding the susceptibility of a protein to degradation by digestive enzymes can be leveraged to address the potential for exposure to intact proteins when consumed as part of a diet (Hammond et al., 2013; Kier and Petrick, 2008) . Most proteins consumed in the diet are completely degraded as part of the digestive process through exposure to acidic conditions and digestive enzymes such as various pepsins in the stomach, or through sequential exposure to acid/pepsin in the stomach followed by pancreatic proteases (e.g. trypsin, chymotrypsin, and carboxypeptidase) secreted into the small intestine (Caspary, 1992) . The resulting small peptides and amino acids are absorbed in the small intestine (Caspary, 1992) and are ultimately utilized as an energy source and as building blocks for the synthesis of new proteins. However, some proteins exhibit resistance to proteolytic degradation, which suggests a potential correlation with the allergenic potential of such proteins (Codex Alimentarius, 2009; EFSA, 2010; FAO-WHO, 2001 ). The results presented here indicate that the Cry51Aa2.834_16 protein is rapidly degraded upon exposure to pepsin under physiological conditions. Thus, it is highly unlikely that the Cry51Aa2.834_16 protein will pose any safety concern to human health upon exposure to the intact, full-length protein.
The Cry51Aa2.834_16 protein will be expressed in insectprotected GM cotton MON 87702. In addition to the ready degradation of Cry51Aa2.834_16, dietary exposure to protein from cotton products derived from MON 87702 in commerce will be negligible because processed fractions of cotton consumed by humans is limited to refined cottonseed oil and linters (100% cellulose containing fraction) that contain negligible amounts of protein (Reeves and Weihrauch, 1979) . The processing conditions for producing cottonseed oil are far harsher (Pons Jr. et al., 1955) than the temperature conditions of 55 C or greater that lead to rapid loss of Cry51Aa2.834_16 insecticidal activity. These data indicate that any protein exposure to Cry51Aa2.834_16 in food or feed derived from MON 88702 would be to a denatured/inactive form of the protein.
The weight-of-evidence from the first-tier safety assessment and the negligible potential for exposure strongly support the conclusion that dietary exposure to the Cry51Aa2.834_16 protein will not adversely affect the health of humans or animals. This is consistent with the extensive testing of Cry proteins expressed in GM crops showing no evidence of toxicity towards humans or animals (Koch et al., 2015; McClintock et al., 1995) . Nevertheless, a toxicity study was conducted with Cry51Aa2.834_16, to confirm the safety of this protein and support international regulatory requirements for the approval of GM cotton. Most known protein toxins exert their toxicity after acute dietary exposure (Hammond and Fuchs, 1998) , therefore an acute mouse oral gavage toxicity study was considered appropriate to assess the toxicity of Cry51Aa2.834_16. Whereas the process of modifying Cry51Aa2 to contain the amino acid modifications present in Cry51Aa2.834_16 utilized selected amino acid sequence changes to significantly increase insecticidal activity against targeted insect pests (Gowda et al., 2016) , no evidence of toxicity was observed when the Cry51Aa2 variants Cry51Aa2.834 and Cry51Aa2.834_2 were tested in mice at doses in excess of 1000 mg/kg body weight or when Cry51Aa2.834_16 was administered orally to mice at a dose of 5000 mg/kg body weight. In the case of Cry51Aa2.834_16, the 5000 mg/kg dose level exceeds the standard limit dose guidance of 2000 mg/kg for acute toxicity studies (OECD, 2008) . These dose levels are exceedingly high relative to low levels of anticipated human exposures due to limited human consumption of protein containing fractions from cotton and the tested dose levels therefore represent robust assessments of the evaluated proteins.
The data presented herein provide direct experimental evidence that despite changes introduced into the Cry51Aa2 protein amino acid sequence resulting in significant enhancement of insecticidal activity, the resulting variant proteins retain the safety profile of the wild-type progenitor, presenting no additional hazard to humans or livestock. Amino acid modifications made to Cry51Aa2.834_16 thus do not make this non-toxic protein into a toxic protein from a mammalian safety perspective, nor do these changes broadly expand the insecticidal activity spectrum unexpectedly beyond that of the wild type progenitor protein. The lack of mammalian toxicity of these Cry51Aa2 proteins to mammals is consistent with the similarity to the ETX_MTX2 family of proteins being largely localized to the pore-forming and oligomerization domains and with sequence diversity found within the specificity-conferring head region of these b-PFPs (Moar et al., 2017) (Fig. 1) .
Evidence from both Tier I evaluation and Tier II toxicity studies provide a case study validating the use of a domain-based approach to complement the existing weight of the evidence safety assessment for pore forming protein toxins expressed in GM crops. As validated for Cry51Aa2.834_16 by the data presented in this report, a weight-of-evidence approach that leverages structural (both at the domain and amino acid sequence levels) and mechanistic knowledge enables and promotes hypothesis-based toxicological evaluations of new proteins for use in the agricultural sector and beyond.
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